Surveys - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PharmTech Poll
Poll archive button
What has been the most significant development in biologic-based drug manufacturing over the past 10 years?
Improvement in upstream yields:
21%
Advancement of single-use technologies or disposables:
28%
Application of quality-by-design principles:
30%
Improvements in downstream bioprocessing/purification:
21%
Other Surveys
Application of QbD
Benefit of Applying QbD Principles
INTERPHEX 2013
Reputation of the Pharma Industry
Biosimilars
PAT Advances
Regulatory Enforcement
Industry Changes
Tablet Splitting
Trade Shows
Patent Cliff
FDA confidentiality
Preventing counterfeiting
European Pharmacovigilance Activities
Generic Drug User Fees Amendments of 2012
European Legislation
Drug Settlements
Emerging Markets
Energy Efficiency
Affordable Care Act
Drug Shortages
Transparency
Significant changes
Quality Management
Analytical equipment
DTC Advertising
Powder properties
Sterile manufacturing
Social Media
API Manufacturing
Lyophilization Advances
Injection technologies
Oral drug delivery
Generic-Drug User Fees
Solid Dosage Innovation
Small-Molecule API Outsourcing
USP Monographs
Anticounterfeiting Solutions
FDA's Enforcement Strategy
Quality by Design and APIs
Outsourcing Biologics
FDA Biosimilars Pathway
Highly potent APIs
Biosimilars
Emerging markets
Strategies for Emerging Markets
Atypical actives
Shared audits
Continuous processing
Carbon Footprints
Immediate-release drug delivery
QbD and CMC
INTERPHEX 2011
FDA Transparency
Tableting equipment
Outsourcing Levels
FDA Recalls
Granulation Techniques
Pharma Forecast for 2011
Needleless devices
Trade Show Attendance
Regulation of excipients
Generic-Drug User Fees
Cleanroom Challenges
Small-Molecule Outsourcing
Pharma packaging
Recall News
Single-use technologies
Pay-to-Delay
Outsourcing concerns
Outsourcing
Green Manufacturing Efforts
Biosimilars: Threat or Opportunity?
Expanding FDA's Power
Anticounterfeiting solutions
Novel Excipients
Tablet manufacture
Equipment Purchasing
Healthcare Reform and Pharma
PharmTech Poll: Recession
Ingredient Suppliers
FDA Spending
PharmTech Poll: CMO Market
PharmTech Poll: Lyophilization
PharmTech Poll: Pharma's Economic Recovery
PharmTech Poll: 2010 M&As
PharmTech Poll: Pharma Forecast for 2010
PharmTech Poll: Oral Drug Delivery
PharmTech Poll: Drug Delivery Technology
PharmTech Poll: The Next Generation of Innovators
PharmTech Poll: Aseptic Techniques
PharmTech Poll: FDA's 2nd Transparency Meeting
PharmTech Poll: Small-Molecule Contract Manufacturing
PharmTech Poll: Packaging Innovation
PharmTech Poll: Implementing Green Chemistry
PharmTech Poll: FDA's Enforcement Plan
PharmTech Poll: Counterfeit Drug Regulation
PharmTech Poll: Biologics Data Exclusivity
Green packaging

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Click here